Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 3:10 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1273–1296 of 9,377 matching trials from the live ClinicalTrials.gov search.

Filters: Portland, Oregon Clear all

Conditions: Cystic Fibrosis, Exocrine Pancreatic Insufficiency
Interventions: Liprotamase, Placebo; Drug
Lead sponsor: Anthera Pharmaceuticals; Industry
Eligibility: 7 Years and older
Enrollment: 163 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 29
States / cities: Los Angeles, California • Stanford, California • Denver, Colorado + 26 more

Conditions: Liver and Intrahepatic Bile Duct Carcinoma, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8, Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8, Unresectable Intrahepatic Cholangiocarcinoma
Interventions: Dexamethasone, Floxuridine, Implanted Medical Device, Irinotecan, Leucovorin, Oxaliplatin, Quality-of-Life Assessment; Drug · Device · Other
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Stress Disorders, Post-Traumatic
Interventions: Prolonged Exposure, Present Centered Therapy; Procedure
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 18 Years and older · Female only
Enrollment: 284 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2006
U.S. locations: 13
States / cities: Denver, Colorado • Bay Pines, Florida • Decatur, Georgia + 10 more

Conditions: Breast Cancer
Interventions: chemotherapy; Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older · Female only
Enrollment: 624 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2017
U.S. locations: 296
States / cities: Anniston, Alabama • Anchorage, Alaska • Jonesboro, Arkansas + 210 more

Conditions: Leukemia, Myelocytic, Acute
Interventions: Fludarabine and Busulfan, Fludarabine and Melphalan, Busulfan and Fludarabine, Busulfan and Cyclophosphamide, Cyclophosphamide and Total Body Irradiation; Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years to 65 Years
Enrollment: 272 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 32
States / cities: Phoenix, Arizona • La Jolla, California • Gainesville, Florida + 27 more

Conditions: Multiple Sclerosis
Interventions: teriflunomide; Drug
Lead sponsor: Providence Health & Services; Other
Eligibility: 21 Years to 60 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2022
U.S. locations: 3
States / cities: Phoenix, Arizona • Latham, New York • Portland, Oregon

Conditions: Acute Myeloid Leukemia
Interventions: Azacitidine, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Gilteritinib, Venetoclax; Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 226
States / cities: Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 179 more

Conditions: Age Related Macular Degeneration
Interventions: Subretinally injected RetinoStat; Drug
Lead sponsor: Oxford BioMedica; Industry
Eligibility: 50 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 3
States / cities: Iowa City, Iowa • Baltimore, Maryland • Portland, Oregon

Conditions: Traumatic Brain Injury
Interventions: Not listed
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 576 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 37
States / cities: Phoenix, Arizona • Tucson, Arizona • Palo Alto, California + 25 more

Conditions: Major Depressive Disorder
Interventions: desvenlafaxine succinate sustained release, fluoxetine, placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 7 Years to 17 Years
Enrollment: 340 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 41
States / cities: Dothan, Alabama • Goodyear, Arizona • Tucson, Arizona + 31 more

Conditions: First Line Non-Small Cell Lung Cancer
Interventions: Avelumab, Pemetrexed, Paclitaxel, Gemcitabine, Carboplatin, Cisplatin, Avelumab Weekly; Drug
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,214 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 21
States / cities: Huntsville, Alabama • Surprise, Arizona • San Diego, California + 18 more

Conditions: Coronary Artery Disease, Myocardial Ischemia
Interventions: No intervention; Other
Lead sponsor: Keya Medical; Industry
Eligibility: 18 Years and older
Enrollment: 302 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 5
States / cities: Fort Lauderdale, Florida • Kansas City, Kansas • Portland, Oregon + 2 more

Conditions: Childhood Hepatocellular Carcinoma, Childhood Malignant Liver Neoplasm, Fibrolamellar Carcinoma, Hepatoblastoma, Hepatocellular Malignant Neoplasm, Not Otherwise Specified
Interventions: Biospecimen Collection, Carboplatin, Cisplatin, Doxorubicin, Etoposide, Fluorouracil, Gemcitabine, Irinotecan, Oxaliplatin, Patient Observation, Resection, Sorafenib, Vincristine Sulfate; Procedure · Drug · Other
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 30 Years
Enrollment: 537 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 180
States / cities: Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 134 more

Conditions: Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions: carboplatin, gemcitabine hydrochloride, paclitaxel; Drug
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1998
U.S. locations: 63
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 50 more

Conditions: Melanoma
Interventions: Dabrafenib, Vemurafenib, Trametinib; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 704 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 36
States / cities: Birmingham, Alabama • Gilbert, Arizona • Beverly Hills, California + 30 more

Conditions: Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Myelodysplastic Syndrome (MDS)
Interventions: CPX-351; Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 5
States / cities: Indianapolis, Indiana • Westwood, Kansas • Portland, Oregon + 2 more

Conditions: Lymphoma
Interventions: rituximab, CHOP regimen, cyclophosphamide, doxorubicin hydrochloride, prednisone, vincristine sulfate; Biological · Drug
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 60 Years and older
Enrollment: 630 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2006
U.S. locations: 91
States / cities: Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 60 more

Conditions: Castrate-Resistant Prostate Cancer, Hormone Refractory Prostate Cancer
Interventions: custirsen sodium, isotonic, 0.9% sodium chloride, docetaxel, cabazitaxel, prednisone; Drug
Lead sponsor: Achieve Life Sciences; Industry
Eligibility: 18 Years to 99 Years · Male only
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 20
States / cities: La Verne, California • Fort Lauderdale, Florida • Tampa, Florida + 17 more

Conditions: Leukemia
Interventions: filgrastim, cyclophosphamide, cytarabine, daunorubicin hydrochloride, dexamethasone, etoposide, leucovorin calcium, mercaptopurine, methotrexate, pegaspargase, therapeutic hydrocortisone, vincristine sulfate, radiation therapy; Biological · Drug · Radiation
Lead sponsor: Children's Oncology Group; Network
Eligibility: 18 Months to 29 Years
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 135
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 116 more

Conditions: Parkinson's Disease, Dyskinesias, Movement Disorders
Interventions: Buspirone, Placebo; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 99 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Non Small Cell Lung Cancer, Advanced Non Small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer, Carcinoma Non Small Cell Lung
Interventions: Ubamatamab, Marlotamig, Sarilumab; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 18
States / cities: Birmingham, Alabama • Goodyear, Arizona • Irvine, California + 14 more

Conditions: Acromegaly
Interventions: Paltusotine, Placebo; Drug
Lead sponsor: Crinetics Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 6
States / cities: Aurora, Colorado • Boston, Massachusetts • Columbus, Ohio + 3 more

Conditions: Acute Respiratory Failure
Interventions: Colorimetric carbon dioxide (CO2) detection, Waveform capnography; Diagnostic Test
Lead sponsor: Brian Driver; Other
Eligibility: 18 Years and older
Enrollment: 2,101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 9
States / cities: Chicago, Illinois • Burlington, Massachusetts • Minneapolis, Minnesota + 6 more

Conditions: Pregnancy
Interventions: medical abortion; Drug
Lead sponsor: Gynuity Health Projects; Other
Eligibility: 10 Years to 50 Years · Female only
Enrollment: 413 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 15
States / cities: Denver, Colorado • Washington D.C., District of Columbia • Atlanta, Georgia + 12 more

Search by objective public record fields.

Liprotamase Efficacy Trial in Patients With Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency

mFOLFIRINOX Followed by Hepatic Arterial Infusion of Floxuridine and Dexamethasone With Systemic mFOLFIRI for Unresectable Liver-dominant Intrahepatic Cholangiocarcinoma

A Randomized Clinical Trial of Cognitive-Behavioral Treatment for Post-Traumatic Stress Disorders in Women

S0500 Treatment Decision Making Based on Blood Levels of Tumor Cells for Metastatic Breast Cancer Treated With Chemo

Reduced Intensity Regimen vs Myeloablative Regimen for Myeloid Leukemia or Myelodysplastic Syndrome (BMT CTN 0901)

MAIN STUDY: SWITCH SUB-STUDY: SWITCH-JCV

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

Phase I Dose Escalation Safety Study of RetinoStat in Advanced Age-Related Macular Degeneration (AMD)

Blood Biomarkers of Injury and Outcome in Traumatic Brain Injury

A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD

Avelumab in First-line NSCLC (JAVELIN Lung 100)

The ADAPT Study: Assessment of the DiAgnostic Performance of DeepVessel FFR in SuspecTed Coronary Artery Disease

Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery

Combination Chemotherapy in Treating Patients With Previously Untreated Stage III or Stage IV Ovarian or Primary Peritoneal Cancer

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

An Open Label Phase II Pharmacokinetic and Pharmacodynamic Assessment of the Potential for QTc Prolongation Following First Induction Treatment With CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in Acute Leukemias and MDS Patients

Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Older Patients With Non-Hodgkin's Lymphoma

A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)

Combination Chemotherapy and Radiation Therapy in Treating Patients With Acute Lymphoblastic Leukemia That Has Relapsed in the CNS or Testes

Buspirone, in Combination With Amantadine, for the Treatment of Levodopa-induced Dyskinesia

A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (PATHFNDR-2)

Waveform Capnography Compared to Colorimetric Carbon Dioxide Detection During Tracheal Intubation of Critically Ill Adults

Feasibility of Telemedicine Medical Abortion